BioSpace News Archive

Pharm Country

Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic

The topline results indicate that the generic product is bioequivalent to the branded product.

January 10, 2018
·
4 min read
SurgaColl Holdings Ltd Announces Series A Funding, Opens HQ in Alderley Park

Surgacoll today announced the completion of its Series A funding, led by the GM&C Life Sciences Fund, and including investment from Julz Co, a US-based healthcare fund.

January 10, 2018
·
2 min read
Drug Development

Radiomedix and AREVA Med Announce Initiation of Phase I Clinical Trial of Alphamedix, a Targeted Alpha Therapy for Patients With Neuroendocrine Tumors

Patients will be enrolled at Excel Diagnostic and Nuclear Oncology Center (Houston, TX).

January 10, 2018
·
4 min read
Emerald Announces Closing of $15M Prospectus Sale

Each Unit consisted of one common share of the Company and one common share purchase warrant (a “Warrant”).

January 10, 2018
·
4 min read
Ablynx: Publication In Accordance With Article 14 of The Belgian Law Of 2 May 2007 Regarding The Publication of Major Shareholdings (The “Transparency Law”) - Jan. 10, 2018

The company received a notification of shareholdings from Consonance CapMan GP LLC on 5 January 2018.

January 10, 2018
·
4 min read
Biotech Bay

Anthera Pharmaceuticals Announces Second Closing of $15M Private Placement Offering

The PIPE transaction was previously announced in October 2017.

January 10, 2018
·
2 min read
Pharm Country

Dynamk Capital Invests in FloDesign Sonics, a Game-Changer for Cell Therapy

Dynamk Capital, a life sciences venture capital fund, today announced an exciting new investment in advancing the commercial production of CAR T and immunotherapies by adding FloDesign Sonics to its growing portfolio.

January 10, 2018
·
2 min read
FDA

Vertex Receives EU Approval for ORKAMBI (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation

Vertex today announced that the European Commission has granted extension of the Marketing Authorization for ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, to include children ages 6 through 11.

January 10, 2018
·
6 min read
BioCapital

Fluke Biomedical VT650 and VT900 Gas Flow Analyzers Offer the Highest Accuracy on the Market

Fluke Biomedical introduces the VT650 and VT900 Gas Flow Analyzers, which include one-channel, full-range air flow functionality that streamlines testing.

January 10, 2018
·
2 min read
Business

Genentech Sets Up New Program for New Combo R&D Deal With Syndax

The trial will assess the efficacy, safety, and pharmacokinetics of immunotherapy combination in HR+, HER2- metastatic breast cancer.

January 10, 2018
·
5 min read